Isosilybin

Other Names

(2R,3R)-2-[2,3-Dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one(2R,3R)-3,5,7-Trihydroxy-2-(2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)chroman-4-one(2R,3R)-3,5,7-Trihydroxy-2-[(2R,3R)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one(2R,3R)-3,5,7-Trihydroxy-2-[(2S,3S)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydro-4H-chromen-4-one(2R,3R)-3,5,7-trihydroxy-2-[(2S,3S)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one(2R,3R)-3,5,7-Trihydroxy-2-[(2S,3S)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydrobenzo[1,4]dioxin-6-yl]-4-chromanone4H-1-Benzopyran-4-one, 2-[(2R,3R)-2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-trihydroxy-4H-1-Benzopyran-4-one, 2-[(2S,3S)-2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)-4H-1-Benzopyran-4-one, 2-[2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl]-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)-iso-Silybiniso-Silybin BIsosilibininIsosilibinin BIsosilybin AIsosilybin BIsosilybininIsosilybinin BSilybin B

Synopsis

Isosilybin: A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Nomenclature and Classification

Isosilybin is a flavonolignan — a structural hybrid of a flavonoid and a lignan — belonging to the same chemical family as silybin (silibinin), silychristin, and silydianin. It belongs to the flavonoid group known as flavonolignans. The term "isosilybin" commonly refers to a pair of diastereomers designated isosilybin A (CAS 142796-21-2; PubChem CID 11059920) and isosilybin B (CAS 142796-22-3; PubChem CID 10885340). Both share the molecular formula C₂₅H₂₂O₁₀. Isosilybin is also referred to in the literature as isosilibinin or isosilybinin, and the combined mixture is sometimes denoted isosilibinin when discussed collectively.

Two pairs of diastereoisomeric flavonolignans, silybin A, silybin B, isosilybin A, and isosilybin B, were successfully separated from Silybum marianum by sequential silica gel column chromatography, preparative reversed-phase HPLC, and recrystallization. On the basis of X-ray crystallographic analysis and optical rotation data, coupled with comprehensive NMR spectral data interpretation, the stereochemistry of the diastereoisomers was determined as: isosilybin A — 2R, 3R, 7′R, 8′R; and isosilybin B — 2R, 3R, 7′S, 8′S.

Structurally, isosilybin and silybin share the same atomic composition but differ in the connectivity of their phenylpropanoid moiety. The silybin/isosilybin structure consists of two main units: the first is based on taxifolin, and the second is a phenylpropanoid unit — in this case coniferyl alcohol — and these two units are linked together into one structure by an oxeran ring. Only silybins and isosilybins contain the 1,4-dioxane ring system in their structure. Silybin and isosilybin have the same trans conformation of C-2, C-3, and C-7′ and C-8′. The positional difference between silybin and isosilybin lies in the regiochemistry of the ether bond connecting the taxifolin and phenylpropanoid fragments; in isosilybin the bond involves a different carbon of the coniferyl alcohol moiety compared with silybin.

1.2 Natural Source and Botanical Context

Silybum marianum is a species of thistle with various common names including milk thistle, blessed milkthistle, Marian thistle, Mary thistle, Saint Mary's thistle, Mediterranean milk thistle, variegated thistle, and Scotch thistle; it is an annual or biennial plant of the family Asteraceae. It is native from around the Mediterranean and much of Europe to Central Asia and India; in Africa it reaches as far south as Ethiopia.

The seed-like fruits (achenes) of milk thistle are the medicinal parts of the plant. Silymarin represents 1.5–3% of the fruit's dry weight and is an isomeric mixture of unique flavonoid complexes — flavonolignans. Silymarin is an extract of milk thistle seeds. Silymarin's primary constituents are the flavonolignan isomers silybins A and B, isosilybins A and B, silychristin (also known as silichristin), silydianin (also known as silidianin), and their flavonoid precursor, taxifolin.

Isosilybin is a minor constituent of silymarin. Silymarin mainly consists of silybin (50–70%) with small amounts of other constituents including isosilybin, silydianin, and silychristin. Because isosilybin constitutes only a small fraction of the total silymarin complex, most historical and commercial preparations have not isolated it individually; rather, it is present as a component within whole silymarin extracts.

1.3 Analytical Separation and Identification

The structural similarity of silybin and isosilybin — and of the A and B diastereomers within each pair — presents significant analytical challenges. Silybin A, silybin B, isosilybin A, and isosilybin B have similar ¹H and ¹³C NMR spectra and no characteristic signals for easy identification of individual isomers. Reversed-phase HPLC shows significant differences in retention times for these isomers, and these diastereoisomeric pairs were separated by sequential silica gel column chromatography, preparative reversed-phase HPLC, and recrystallization from CH₂Cl₂/MeOH, allowing isolation of pure diastereoisomers. A consequence of this difficulty is that many older studies on "silymarin" or "silibinin" did not resolve or individually quantify isosilybin, and activities attributed to the bulk extract may reflect contributions from multiple constituents.

1.4 Common Forms and Preparations

Because of the lipophilic nature of its active constituents, milk thistle is usually administered as an extract in capsule or tablet form rather than as a tea or infusion. Special formulations of silymarin and/or the silybins have been developed to enhance their bioavailability by conjugation with phosphatidylcholine. Most supplements are standardized according to their silybin content. Because isosilybin A and B together represent a small proportion of silymarin, no commercially approved pharmaceutical product isolates isosilybin as its sole active constituent; isosilybin is instead obtained as a purified research compound, typically produced by chromatographic separation from silymarin extract, and used in preclinical studies. In some European countries, silibinin is available as part of the silymarin extract for oral use and as a water solution containing the dihemisuccinate disodium salt for intravenous injection; the extract is also available in other regions as a dietary supplement.

2. Traditional and Historical Use

The traditional uses of isosilybin cannot be separated historically from those of the whole plant Silybum marianum and its crude extract silymarin, because isosilybin as an isolated compound was not identified until the modern chemical era. All traditional knowledge pertains to preparations of the whole plant or seed, within which isosilybin was an unrecognized minor constituent.

Milk thistle (Silybum marianum) is a medicinal plant that has been used for thousands of years as a remedy for a variety of ailments. The Greek physician Dioscorides was among the first to document its medicinal applications in the first century AD. Milk thistle was traditionally used to treat jaundice, hepatitis, and other liver-related conditions. The first-century Roman author and scientist Pliny wrote of milk thistle as a wholesome food.

In important medieval medical books such as Matthiolus' Book of Herbs of 1626, it is recommended "for side stitches which accompany jaundice." In his Book of Herbs of 1679, Lonicerus writes that "it is good for an inflamed liver." The well-known 17th-century pharmacist Nicholas Culpeper recommended the plant for the treatment of jaundice and also cited its use for opening "obstructions" of the liver and spleen.

Historically, milk thistle was used for liver disorders and to increase breast milk production. It has also been discovered that Indian and Chinese medicines used Silybum marianum in clinical practice for liver and gallbladder problems. Claims have been made since ancient times that the active flavanoid-lignan group of constituents, called silymarin, contained only in the seed shell, has liver-protective and regenerative properties, as well as antioxidant effects. Chemical, pharmacological, and safety research started in Germany in the 1950s.

Although milk thistle has been used medicinally for over 2000 years, the active hepatoprotective constituent, silymarin, was first isolated from the seeds (fruit) in 1968. Individual flavonolignans — including isosilybin A and isosilybin B as discrete diastereomers — were not fully characterized until the early 2000s, when advances in NMR spectroscopy and HPLC enabled their unambiguous separation and stereochemical assignment.

In 2018, the European Medicines Agency published an assessment report on the oral use of milk thistle fruit and its extracts in EU states. It finds that there is a "well-established use" of hepatoprotection approved by 11 countries and a "traditional use" of dyspeptic complaints in 4 countries. EMA has also published a monograph on this herbal substance.

3. Key Constituents and Chemical Context within Silymarin

To understand isosilybin's pharmacological profile, it is essential to place it within the composition of silymarin. The active substance in milk thistle, silymarin, is a complex mixture of flavonolignans. Silymarin's primary constituents are the flavonolignan isomers silybins A and B, isosilybins A and B, silychristin (also known as silichristin), silydianin (also known as silidianin), and their flavonoid precursor, taxifolin.

The silymarin flavonolignans (e.g., silybin, isosilybin, silychristin) each have a number of hydroxyl and phenolic groups in their structures. These phenolic and hydroxyl moieties underlie the antioxidant properties shared across the class. Silymarin and other polyphenolic compounds, despite extensive research on their potential pharmacological effects, should be interpreted with caution due to the chemical nature of polyphenolic compounds, which can act as pan-assay interference compounds (PAINS). PAINS are known to generate false-positive or artefactual findings in biochemical and cellular assays due to non-specific interactions that are not related to true pharmacological effects. This caveat applies particularly to in vitro screening studies of all silymarin constituents including isosilybin.

A key distinction is that isosilybin A and isosilybin B are not simply stereochemical variants with identical biology; available evidence indicates that isosilybin B is the more biologically potent diastereomer in several assays. Diastereoisomer B, but not A of isosilybin attenuated steatosis in hepatocytes in one lipid-metabolism study. Similarly, in anticancer comparisons, isosilybin B has generally shown greater potency than isosilybin A at equivalent concentrations, though the two diastereomers share many mechanistic targets.

4. Established Mechanisms of Action

4.1 Antioxidant Activity

The extract from milk thistle (Silybum marianum), known as silymarin, contains a variety of flavonolignans and displays antioxidant, anti-inflammatory, immunomodulatory, and hepatoprotective properties. Isosilybin contributes to antioxidant activity through multiple mechanisms. Isosilybin A inhibits lipid peroxidation in rat liver microsomes (IC₅₀ = 32 μM) and reduces ADP/Fe³⁺-induced malondialdehyde (MDA) production and lactate dehydrogenase (LDH) release in rat hepatocytes. Isosilybin A inhibits the production of reactive oxygen species (ROS), MDA and LDH release, and reduction in total antioxidant capacity induced by amyloid-β (25-35) in HT-22 hippocampal cells. It also increases protein and mRNA expression of heme oxygenase-1 (HO-1), glutathione S-transferase (GST), and the aldo-keto reductases (AKR1C1 and AKR1C2) in HT-22 cells.

In a pharmacokinetic study in healthy human volunteers, urinary 8-epi-prostaglandin F_2α — a biomarker of oxidative stress — was measured. The concentrations of urinary 8-epi-prostaglandin F_2α were considerably decreased in study subjects after a 28-day exposure to the silymarin extract (1.3 ± 0.9 versus 0.8 ± 0.9 ng/mg creatinine). This finding reflects the combined antioxidant effect of the silymarin constituents, including isosilybin, though the individual contribution of isosilybin cannot be separated from the mixture in this human study.

4.2 PPARγ Agonism and Lipid/Glucose Metabolism

Peroxisome proliferator-activated receptor gamma (PPARγ) is a key regulator of glucose and lipid metabolism. Agonists of this nuclear receptor are used in the treatment of type 2 diabetes and are also studied as a potential treatment of other metabolic diseases, including nonalcoholic fatty liver disease.

In a 2014 study, the PPARγ activation potential of silymarin and its main constituents was investigated. Isosilybin A caused transactivation of a PPARγ-dependent luciferase reporter in a concentration-dependent manner. This effect could be reversed upon co-treatment with the PPARγ antagonist T0070907. Isosilybin A caused transactivation of a PPARγ-dependent luciferase reporter in a concentration-dependent manner; this effect could be reversed upon co-treatment with the PPARγ antagonist T0070907. In silico docking studies suggested a binding mode for isosilybin A distinct from that of the inactive silymarin constituents, with one additional hydrogen bond to Ser342 in the entrance region of the ligand-binding domain of the receptor. Hence, isosilybin A has been identified as the first flavonolignan PPARγ agonist.

As a consequence of PPARγ partial agonism, isosilybin A, silybin B, silychristin, and isosilychristin were found to significantly induce ABCA1 protein expression without affecting cell viability. Moreover, isosilybin A, a partial PPARγ agonist, was found to promote cholesterol efflux from THP-1 macrophages in a concentration-dependent manner. These findings show the ABCA1 protein up-regulating activity of active constituents of silymarin and provide new avenues for their further study in the context of cardiovascular disease.

4.3 AMPK-Mediated Lipid Metabolism Regulation

Isosilybin significantly reduced triglyceride (TG) levels in free fatty acid (FFA)- and TO901317-induced HepG2 cells. Further studies showed that isosilybin treatment decreased the mRNA and protein expression of lipid synthesis genes Srebp-1c, Pnpla3, Acc, and Fas, as well as the mRNA expression of the fatty acid uptake gene CD36, whereas it increased the mRNA levels of lipid oxidation genes Pparα, Acox1, and Cpt1α, as well as the mRNA expression of the lipid export gene Mttp, in FFA-induced HepG2 cells. An increased level of phosphorylated AMP kinase (AMPK) was observed after isosilybin treatment, while this effect was reversed after further treatment with AMPK inhibitor compound C. These results suggest that isosilybin can inhibit lipid synthesis and activate lipid oxidation through the AMPK signaling pathway, thereby improving steatosis of hepatocytes, and isosilybin B is the basis of its active substance.

4.4 Androgen Receptor and Oncogenic Signaling

Both diastereomers have been studied for their ability to interfere with the androgen receptor (AR) and related oncogenic pathways in prostate cancer cells. The mechanisms differ somewhat between the two:

For isosilybin B, the primary identified mechanism involves AR degradation via the PI3K–Akt–Mdm2 pathway. Isosilybin B (10–90 μM) treatment decreased AR and prostate specific antigen (PSA) levels in LNCaP, 22Rv1, and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells. Isosilybin B treatment also inhibited synthetic androgen R1881-induced nuclear localization of AR, PSA expression and cell growth, and caused G1 arrest. In mechanistic studies, isosilybin B caused increased phosphorylation of Akt (Ser-473 and Thr-308) and Mdm2 (Ser-166), which was linked with AR degradation. Overexpression of kinase-dead Akt largely reversed isosilybin B-mediated AR degradation, suggesting a critical role of Akt in AR degradation. Antibody pull-down results also indicated that isosilybin B treatment enhances the formation of a complex between Akt, Mdm2, and AR, which promotes phosphorylation-dependent AR ubiquitination and its degradation by the proteasome.

For isosilybin A, apoptosis induction in prostate cancer cells appears to proceed through the Akt–NF-κB–AR axis. Isosilybin A (90–180 μM) treatment significantly induced apoptotic death by activating both extrinsic (increased level of DR5 and cleaved caspase-8) and intrinsic pathways (caspase-9 and -3 activation) in three different human prostate cancer cell lines (22Rv1, LAPC4, and LNCaP). Further, isosilybin A treatment decreased the levels of phospho-Akt (Ser-473), total Akt, and the nuclear levels of NF-κB constituents (p50 and p65). Isosilybin A treatment also decreased AR and PSA levels in 22Rv1, LAPC4, and LNCaP cells.

4.5 Cell Cycle Arrest

Both diastereomers share the capacity to induce cell cycle arrest. Isosilybin B and isosilybin A treatment resulted in growth inhibition and cell death together with a strong G1 arrest and apoptosis in both prostate cancer cell lines tested. In studies examining changes in cell cycle and apoptosis regulators, isosilybin B and isosilybin A resulted in a decrease in the levels of both cyclins (D1, D3, E, and A) and cyclin-dependent kinases (Cdk2, Cdk4, and cell division cycle 25A), but caused an increase in p21, p27, and p53 levels, except in 22Rv1 cells where isosilybin B caused a decrease in p21 protein level. Isosilybin B- and isosilybin A-induced apoptosis was accompanied with an increase in the cleavage of poly(ADP-ribose) polymerase, caspase-9, and caspase-3, and a decrease in survivin levels.

4.6 Anti-inflammatory and Immunomodulatory Mechanisms

In a comprehensive study, all major silymarin flavonolignans and the flavonoid taxifolin were tested side by side across multiple hepatoprotective assays, including antiviral activity, NF-κB inhibition, antioxidant function, and T-cell immunomodulation. Compounds such as isosilybin A and silybin A outperformed silybin in several assays, particularly in antiviral, anti-inflammatory, and T-cell proliferation activity. These studies are in vitro and preclinical in nature; their clinical relevance has not been established in controlled human trials specific to isosilybin.

4.7 CYP450 Inhibition

In vitro results suggest a potentially significant inhibitory effect of isosilibinin and isosilybin B on CYP2C8 activity. However, the observed IC₅₀ values are unlikely to be achieved in humans supplemented with orally administered milk thistle extracts due to the poor bioavailability of flavonolignans documented with most commercially available formulations. Additionally, isosilybin inhibits CYP3A4 induction with an IC₅₀ of 74 μM in vitro, and isosilybin and silybin might be suitable candidates to design potent PXR antagonists to prevent drug–drug interactions via CYP3A4 in cancer patients.

5. Scientific Evidence by Area of Use

5.1 Hepatoprotection and Liver Disease

Background: Silybum marianum (milk thistle) is a plant for centuries well known for its hepatoprotective effects. The extract from seeds, silymarin, and its major compound, silibinin, are well studied for their hepatoprotective and antifibrotic effects. The role of other minor compounds, such as isosilybin B, remains underexplored.

In vitro evidence (antifibrotic): A 2025 in vitro study by Selc et al. (Discover Oncology) directly compared the cytotoxic and antifibrotic properties of isosilybin B with silibinin and silymarin in liver cancer cells (Hepa1-6 and HepG2) and normal hepatocytes (AML12). Isosilybin B exhibits greater cytotoxicity toward liver cancer cells while being less toxic to non-tumor hepatocytes compared to silibinin. At non-toxic concentrations, isosilybin B induced cell cycle arrest at the G1 phase in two types of liver cancer cells. In contrast, it did not impact the cell cycle of non-tumor cells under the same experimental conditions. In the model of liver fibrosis in vitro induced by TGF-β1, isosilybin B reduced the mRNA expression of pro-fibrotic genes as well as ALT level in the culture medium more effectively than silibinin.

The ability of isosilybin B to selectively induce G1 cell cycle arrest in liver cancer cells but not in non-tumor hepatocytes, which was not observed with silymarin and silibinin, suggests its potential role in anticancer therapy targeting hepatocellular carcinoma. However, future studies should investigate these mechanisms in more depth and shift the focus towards in vivo models.

Evidence strength: All current hepatoprotective evidence for isosilybin specifically is at the in vitro (cell culture) level. No clinical trials in humans have been conducted using isolated isosilybin for liver disease. Evidence is preliminary and must be considered hypothesis-generating.

5.2 Nonalcoholic Fatty Liver Disease (NAFLD) and Lipid Metabolism

The excessive accumulation of lipid in hepatocytes is one of the important causes of NAFLD. A study explored the effects of isosilybin on lipid metabolism in free fatty acid (FFA)- or TO901317-induced HepG2 cells. Cells were treated with FFAs (oleic acid:palmitic acid, 2:1) or TO901317 to induce steatosis in vitro. The results showed that isosilybin significantly reduced TG levels in FFA- and TO901317-induced HepG2 cells. Isosilybin B was previously shown to reduce triglycerides in HepG2 cells exposed to free fatty acids, while also modulating lipid metabolism-related gene expression. The combination of antifibrotic, hepatoprotective, and triglyceride-lowering effects makes isosilybin B a promising candidate for the treatment of early stages of liver disease.

Evidence strength: Exclusively in vitro. No animal or human studies have been conducted specifically on isolated isosilybin for NAFLD. The broader silymarin literature includes mixed clinical trial results for NAFLD, but these are attributable to the extract as a whole and cannot be disaggregated to isosilybin's contribution.

5.3 Cancer — Prostate

The most extensively studied oncological application of isosilybin concerns prostate cancer, supported by multiple independent in vitro studies.

Study 1 — Growth inhibition and apoptosis (Deep et al., 2007, Carcinogenesis): Two pure compounds, isosilybin B and isosilybin A, isolated from silymarin, were assessed in human prostate carcinoma LNCaP and 22Rv1 cells. Isosilybin B and isosilybin A treatment resulted in growth inhibition and cell death together with a strong G1 arrest and apoptosis in both cell lines. Compared with LNCaP and 22Rv1 cells, the antiproliferative and cytotoxic potentials of isosilybin B and isosilybin A were of much lesser magnitude in non-neoplastic human prostate epithelial PWR-1E cells, suggesting the transformation-selective effect of these compounds. This study for the first time identified that isosilybin B and isosilybin A have anti-PCA activity mediated via cell cycle arrest and apoptosis induction.

Study 2 — AR degradation via PI3K–Akt–Mdm2 (Deep et al., 2008, Oncogene): The identification and development of novel nontoxic phytochemicals that target androgen and AR signaling remains a priority for prostate cancer control. In the present study, the antiandrogenic efficacy of isosilybin B was assessed employing human PCA LNCaP (mutated AR), 22Rv1 (mutated AR), and LAPC4 (wild-type AR) cells. Treatment with isosilybin B (10–90 μM) decreased AR and PSA levels in all three prostate cancer cell lines while sparing non-neoplastic PWR-1E cells. These findings identify a novel mechanism for isosilybin B-mediated anticancer effects in human prostate cancer cells.

Study 3 — Apoptosis via Akt–NF-κB–AR axis, isosilybin A (Deep et al., 2010, Molecular Carcinogenesis): Temporal kinetics analysis showed that the primary effect of isosilybin A is on AR, as a decrease in AR was evident much earlier (4 h) relative to caspase activation and apoptosis induction (12 h). Overall, isosilybin A activates apoptotic machinery in PCA cells via targeting the Akt–NF-κB–AR axis, thereby indicating a promising role for this phytochemical in the management of clinical PCA.

Isosilybin A and isosilybin B were reported nearly two decades ago to selectively induce apoptosis and cause pronounced G1 arrest in prostate cancer cells, while sparing nonmalignant counterparts. This degree of tumor-specific targeting has not been demonstrated for silybin to date.

Evidence strength: All prostate cancer evidence for isosilybin remains at the in vitro cell-line level. No clinical trials in humans using isolated isosilybin have been published. While the mechanistic data are internally consistent across multiple studies, translation to human clinical efficacy is unproven.

5.4 Cancer — Hepatocellular Carcinoma

Isosilybin B exhibits greater cytotoxicity toward liver cancer cells while being less toxic to non-tumor hepatocytes compared to silibinin. At non-toxic concentrations, isosilybin B induced cell cycle arrest at the G1 phase in two types of liver cancer cells. Isosilybin B exhibited cytotoxicity in human hepatoma cells at concentrations above 10 μM, whereas all other tested compounds (in the comparative study) were well tolerated up to 80 μM.

Evidence strength: In vitro only. No animal models or human trials have been conducted for isosilybin in hepatocellular carcinoma specifically. Evidence is highly preliminary.

5.5 Metabolic Disease — PPARγ and Cardiovascular Implications

Isosilybin A caused transactivation of a PPARγ-dependent luciferase reporter in a concentration-dependent manner; this effect could be reversed upon co-treatment with the PPARγ antagonist T0070907. PPARγ is a nuclear receptor that functions as a key regulator of lipid and glucose metabolism. Isosilybin A, silybin B, silychristin, and isosilychristin were found to significantly induce ABCA1 protein expression without affecting cell viability. Moreover, isosilybin A, a partial PPARγ agonist, was found to promote cholesterol efflux from THP-1 macrophages in a concentration-dependent manner. These findings provide new avenues for their further study in the context of cardiovascular disease.

Evidence strength: Cell-based and in silico studies only. No human or animal trials have tested isolated isosilybin specifically for metabolic or cardiovascular outcomes. The broader clinical literature on silymarin for type 2 diabetes and NAFLD cannot be attributed to isosilybin.

5.6 Neuroprotection

Isosilybin A inhibits the production of ROS, MDA, and LDH release, and reduction in total antioxidant capacity induced by amyloid-β (25-35) in HT-22 hippocampal cells. It also increases protein and mRNA expression of HO-1, GST, and the aldo-keto reductases AKR1C1 and AKR1C2 in HT-22 cells. These in vitro findings in a neuronal cell line suggest antioxidant-based neuroprotective potential against amyloid-β-induced toxicity, relevant to Alzheimer's disease modeling.

Evidence strength: Solely in vitro (neuronal cell line). No animal or human studies have examined isosilybin in neurological conditions. Evidence is very preliminary.

6. Pharmacokinetics and Bioavailability

Bioavailability data for isosilybin come primarily from pharmacokinetic studies in human volunteers consuming silymarin extract, in which multiple flavonolignans are measured simultaneously. All six flavonolignans in silymarin were rapidly absorbed and eliminated. In order of abundance, the systemic exposure to free flavonolignans was greatest for silybin A, followed by silybin B, isosilybin B, isosilybin A, silychristin, and silydianin. The systemic exposure to these compounds appeared linear and dose-proportional. The disposition of flavonolignans was stereoselective: the apparent clearance of silybin B was significantly greater than silybin A, whereas the apparent clearance of isosilybin B was significantly lower than isosilybin A.

Although hepatoprotective properties of silybin are well documented, the clinical therapeutic efficacy is limited by its low bioavailability due to absorption rates, extensive phase II metabolism, and biliary excretion. The same constraints apply to isosilybin. Silymarin undergoes phase I and phase II metabolism, especially phase II conjugation reactions, and it undergoes multiple conjugation reactions and is primarily excreted into bile and urine. To address poor bioavailability, special formulations of silymarin and/or the silybins have been developed to enhance their bioavailability by conjugation with phosphatidylcholine; analogous approaches for isolated isosilybin remain investigational.

7. Dosage Forms and Dosages Reported in Studies

Because isosilybin is not available as an approved standalone pharmaceutical product, there are no established therapeutic doses for humans. Doses reported in the scientific literature reflect either the concentrations used in cell culture studies or, in pharmacokinetic studies, doses of the whole silymarin extract from which isosilybin levels were then measured. The following are reported directly from sources:

In vitro prostate cancer studies: Isosilybin B was tested at concentrations of 10–90 μM in LNCaP, 22Rv1, and LAPC4 prostate cancer cells.
In vitro prostate cancer — isosilybin A apoptosis study: Isosilybin A at 90–180 μM significantly induced apoptotic death in three different human prostate cancer cell lines.
Human pharmacokinetic study (silymarin extract): The steady state pharmacokinetic parameters were determined after subjects were administered one capsule thrice daily for 28 consecutive days. The individual isosilybin diastereomer exposures were characterized, showing isosilybin B and isosilybin A as the third and fourth most abundant free flavonolignans in systemic circulation.
PPARγ activation assay: HEK-293 cells were treated with isosilybin A at 30 μM to demonstrate PPARγ transactivation.
CYP3A4 inhibition: Isosilybin inhibits CYP3A4 induction with an IC₅₀ of 74 μM in vitro.

Whole silymarin extract products are commercially available in tablet and capsule forms and are typically standardized to 70–80% total flavonolignan content. Because isosilybin represents only a minor fraction of silymarin, the actual dose of isosilybin received by consumers of commercial silymarin products is substantially lower than the concentrations tested in vitro.

8. Safety Considerations and Drug Interactions

8.1 General Safety Profile

Silymarin has a good safety profile, but little is known regarding its potential for drug interaction. This statement applies to silymarin as a whole; the safety data for isolated isosilybin specifically — as distinct from the mixture — are not available from human clinical studies. Based upon promising results from preclinical studies, silybin has been tested in human cancer patients in phase I–II pilot clinical trials, where it was reported to be well tolerated and showed plasma and target-tissue bioavailability. Several traditional toxicological tests have proven the non-toxic nature of silybin, and it is reported to be safe for human consumption. These findings apply to silybin/silibinin, the dominant constituent, and should not be uncritically extended to minor constituents like isosilybin.

Isosilybin B exhibited cytotoxicity in human hepatoma cells at concentrations above 10 μM, whereas all other tested compounds in the comparative study were well tolerated up to 80 μM. This in vitro finding warrants attention but does not constitute evidence of human toxicity at physiologically relevant concentrations. It does, however, suggest that isolated isosilybin B may have a narrower in vitro therapeutic window than other silymarin constituents.

8.2 CYP450 Enzyme Interactions

Isosilybin has been shown in vitro to interact with cytochrome P450 enzymes. In vitro results suggest a potentially significant inhibitory effect of isosilibinin and isosilybin B on CYP2C8 activity. However, the observed IC₅₀ values are unlikely to be achieved in humans supplemented with orally administered milk thistle extracts due to the poor bioavailability of flavonolignans documented with most commercially available formulations. With respect to CYP3A4, silymarin has limited effect on the pharmacokinetics of several drugs in vivo; despite silymarin decreasing the activity of CYP enzymes and UDP-glucuronosyltransferase enzymes in vitro, meaningful clinical interactions at usual oral doses have not been firmly established. The CYP3A4 inhibition data for isosilybin specifically remain in vitro-only.

8.3 Stereoselectivity and Differential Safety

The existence of two diastereomers (A and B) with distinct biological profiles has safety implications for any future pharmaceutical development. Although isosilybin B shares the same atomic composition as silibinin, it differs in stereochemistry. The observed greater cytotoxicity of isosilybin B toward hepatoma cells compared to normal hepatocytes in vitro, and the less favorable in vitro toxicity profile relative to other silymarin flavonolignans at certain concentrations, underscore the importance of using well-characterized, diastereomer-pure material in any future clinical investigation.

8.4 Quality Variability in Commercial Products

A practical safety concern is the variability of commercially available silymarin products, which directly affects the amount of isosilybin a consumer actually receives. As silybin is the main component of silymarin, the literature mainly focuses on this compound, ignoring all other components. This leads to problems in reproducibility of scientific results, as the exact composition of silymarin is often unknown and can vary to a certain degree depending on the source.

9. Current Research Status and Limitations

The body of scientific evidence on isosilybin is exclusively preclinical. Key limitations include:

No human clinical trials: No randomized controlled trials, phase I, II, or III clinical studies, have been conducted using isolated isosilybin A or isosilybin B as the test agent in human subjects.
In vitro artifact risk: Silymarin and other polyphenolic compounds should be interpreted with caution due to their potential to act as pan-assay interference compounds (PAINS), which can generate false-positive or artefactual findings in biochemical and cellular assays.
Concentration gap: Effective concentrations in cell culture studies (often 10–180 μM) substantially exceed plasma levels achievable by oral consumption of silymarin products, given poor bioavailability.
Historical conflation: Much of the traditional use, and even much older pharmacological research, relates to silymarin or silibinin as a whole; attribution of specific effects to isosilybin requires careful scrutiny of the experimental design.
Underexplored diastereomers: These findings underscore the potential of underrepresented constituents and challenge the prevailing assumption that silybin is the sole bioactive driver of silymarin's effects. Future research distinguishing the A and B forms of isosilybin is needed.

References

Health Conditions

Health conditions that Isosilybin may help support.

Gallbladder HealthTraditional
Isosilybin is a diastereomeric flavonolignan component of the silymarin complex from milk thistle (Silybum marianum). As part of the clinically studied silymarin complex it contributes to the aggregate hepatoprotective and bile-modulating effects used for liver and gallbladder health. Evidence is indirect through the complex.

Body Systems

Body systems that Isosilybin may help support.

No body systems available.